Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04767698
What this trial is testing

Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Johns Hopkins University 4
Not applicableLooking for participantsNCT04458688
What this trial is testing

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Wayne State University 80
Testing effectiveness (Phase 2)Ended earlyNCT01037907
What this trial is testing

Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Boston Scientific Corporation 173
Testing effectiveness (Phase 2)UnknownNCT00151801
What this trial is testing

Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients

Who this might be right for
Multiple Sclerosis
S. Andrea Hospital 200
Large-scale testing (Phase 3)UnknownNCT00242268
What this trial is testing

A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Alabama Neurology Associates, PC 30
Not applicableStudy completedNCT00902135
What this trial is testing

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Bayer 702
Not applicableStudy completedNCT01695434
What this trial is testing

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

Who this might be right for
Multiple Sclerosis
University at Buffalo 60
Not applicableStudy completedNCT03679806
What this trial is testing

Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Dokuz Eylul University 30
Large-scale testing (Phase 3)Study completedNCT00360906
What this trial is testing

Omega-3 Fatty Acid Treatment in Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Haukeland University Hospital 100
Not applicableStudy completedNCT01141751
What this trial is testing

An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 334
Large-scale testing (Phase 3)Study completedNCT01490502
What this trial is testing

Vitamin D Supplementation in Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Johns Hopkins University 172
Large-scale testing (Phase 3)Study completedNCT03689972
What this trial is testing

Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 585
Large-scale testing (Phase 3)Study completedNCT02861014
What this trial is testing

Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Hoffmann-La Roche 681
Not applicableStudy completedNCT01080014
What this trial is testing

Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina

Who this might be right for
Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 252
Not applicableUnknownNCT04030819
What this trial is testing

Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis

Who this might be right for
Anxiety
Paris Nanterre University 106
Testing effectiveness (Phase 2)UnknownNCT01466114
What this trial is testing

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Who this might be right for
Relapsing-remitting Multiple SclerosisSecondary-progressive Multiple SclerosisPrimary-progressive Multiple Sclerosis
University of California, Los Angeles 64
Post-approval studies (Phase 4)UnknownNCT04225312
What this trial is testing

Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Amsterdam UMC, location VUmc 300
Not applicableEnded earlyNCT02323269
What this trial is testing

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingRelapsing-Remitting Multiple Sclerosis
Biogen 24
Not applicableUnknownNCT03508414
What this trial is testing

Nutritional Approaches in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Charite University, Berlin, Germany 111
Not applicableEnded earlyNCT02833714
What this trial is testing

Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

Who this might be right for
RELAPSING REMITTING MULTIPLE SCLEROSIS
University of North Carolina, Chapel Hill 26
Next Page